Merck & Co. joins race for COVID-19 vaccines and therapies
Tuesday, May 26, 2020 - 21:10
in Health & Medicine
The firm will develop viral vector vaccines from IAVI and Themis Bioscience, and the experimental EIDD-2801 antiviral compound developed by Ridgeback Biotherapeutics